{"id":"NCT00543725","sponsor":"Tibotec Pharmaceuticals, Ireland","briefTitle":"TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors","officialTitle":"A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2010-01","completion":"2012-02","firstPosted":"2007-10-15","resultsPosted":"2011-07-12","lastUpdate":"2016-04-01"},"enrollment":680,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections","HIV-1"],"interventions":[{"type":"DRUG","name":"TMC278","otherNames":[]},{"type":"DRUG","name":"efavirenz","otherNames":[]}],"arms":[{"label":"002","type":"ACTIVE_COMPARATOR"},{"label":"001","type":"EXPERIMENTAL"}],"summary":"The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278 given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily, when combined with a background regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors ( investigator choice of ABC/3TC, TDF/FTC or AZT/3TC) in HIV-1 infected patients who have not yet taken any anti-HIV drugs. The following evaluations will be done: antiviral activity, immunologic changes, and viral geno-/phenotype evolution, relationship of Pharmacokinetics (PK) and PK/Pharmacodynamics and Medical resource utilization and treatment adherence.","primaryOutcome":{"measure":"Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"TMC278","deltaMin":291,"sd":null},{"arm":"Efavirenz","deltaMin":276,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":82,"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","China","Costa Rica","France","Germany","India","Mexico","Panama","Portugal","Puerto Rico","Russia","South Africa","Spain","Thailand","United Kingdom"]},"refs":{"pmids":["23714781","22532465","21763935"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":340},"commonTop":["Dizziness","Nausea","Headache","Diarrhoea","Nasopharyngitis"]}}